GVR Report cover Connected Drug Delivery Devices Market Size, Share & Trends Report

Connected Drug Delivery Devices Market Size, Share & Trends Analysis Report By Technology (Bluetooth, NFC), By Product (Connected Sensors, Integrated Connected Devices), By End User, And Segment Forecasts, 2021 - 2028

  • Published Date: Jan, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-2-68038-651-6
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 128

Report Overview

The global connected drug delivery devices market size was valued at USD 214.10 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 46.7% from 2021 to 2028. Increased patient engagement and connectivity owing to the growing penetration of the Internet of Things (IoT) in the medical devices sector is anticipated to drive the market. During the Covid-19 pandemic, the market experienced exponential growth due to the rising demand for drug delivery solutions, which can be used at home. The product is anticipated to continue to witness tremendous growth in the future as well owing to the rising emphasis on the current trend of improved patient compliance and quality of care, increasing awareness regarding production footprint and associated costs, and growing use of self-administered and connected drug therapy.

North America connected drug delivery devices market size, by end user, 2016 - 2028 (USD Million)

Increasing number of programs and initiatives aimed at spreading awareness about the benefits of adherence to therapies prescribed by physicians will also support market growth. Moreover, rising awareness regarding the benefits of connected systems over conventional systems is expected to fuel the product demand, thereby driving the market growth over the forecast period.

Partnerships, collaborations, product approvals & launches, and acquisitions have positively impacted the market in recent years. Market players involved in the development and production of sensors are also conducting various medical programs for the same.

For instance, Propeller Health has organized around 60 connected medical programs to highlight technological challenges associated with the management of drug delivery devices and has added value to connected drug delivery devices. These devices help physicians to monitor the compliance of patients to the therapy prescribed by them as well as to modify treatments as required.

COVID19 connected drug delivery devices market impact: exponential growth of 23.8% from 2019 to 2020

Pandemic Impact

Post COVID Outlook

During the pandemic, market players experienced a high demand for drug delivery solutions intended for home care settings. Previously the market was estimated to be at USD 190 million, however, it is now valued at over USD 214 million in 2020.

The market is expected to continue its growth, to reach USD 279.34 million in 2021. The growing penetration of the IoT in medical devices will propel market growth.

In 2020, the market registered a year-on-year growth rate of 23.8% as compared to 2019, wherein it experienced a 15.5% year-on-year growth rate, due to high demand for the connected drug delivery devices.

Nasal inhalation is an area of active research for the delivery of CNS drugs to cross the blood-brain barrier and also for biologics. This field is expected to witness investments by market players in the coming years.

West Pharmaceutical Services, Inc. experienced an increase of 16.7% in its growth rate from 2019 to 2020, as compared to 7.1% from 2018 to 2019

According to OnDrugDelivery, in 2021, the connected drug delivery devices market is expected to focus on improving the outcomes and experience for individual patients

 

Product Insights

The connected sensors segment dominated the market and accounted for the highest revenue share of over 68% in 2020. Connected sensors can be integrated with the existing delivery devices without interfering with their normal functioning and can be reused even if the device is disposable. These sensors are further divided into connectable injection sensors and connected inhaler sensors. The integrated connected devices segment is expected to register the fastest CAGR over the forecast period. The integrated connected devices segment is also sub-segmented into connected inhalation devices and connected injection devices.

Various advantages of inhalation devices over injection devices, such as needleless drug delivery, have led to increased use of inhalation devices. The increasing incidence of chronic respiratory diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD), is expected to boost the demand for inhalation devices in the market. According to a 2019 study by the Centers for Disease Control & Prevention (CD), globally, 1 out of 13 people suffered from asthma. In addition, increasing connectivity, due to IoT and other technologies, is expected to drive the market in the coming years.

End-user Insights

The healthcare providers segment accounted for the largest revenue share of more than 50.0% in 2020 owing to the increased cases of COPD, Cardiovascular Diseases (CVDs), diabetes, and other chronic diseases, which require proper maintenance of health records of the patient. Connected drug delivery devices monitor the drug usage as well as its delivery and also maintain the health records.

On the other hand, the homecare segment is estimated to register the fastest CAGR from 2021 to 2028 owing to the increasing product acceptance in homecare settings. These devices assist with the administration of medications in homecare settings without any errors linked with drug delivery and without the assistance of healthcare providers. These factors are expected to drive the segment growth.

Technology Insights

The Bluetooth technology segment accounted for the largest revenue share of 65.3% in 2020 owing to the high usage of the Bluetooth technology in drug delivery devices. With the advancements in this technology, the segment is expected to witness significant growth in the coming years. Moreover, the technology is cheaper as well as easily available as compared to NFC and other such technologies.

Global connected drug delivery devices market share, by technology, 2020 (%)

The NFC segment is expected to account for a considerable market share by 2028 as the NFC technology assists in communicating through the internet as well as mobile apps. Furthermore, the technology is highly adopted for drug identification and tracking. The others segment is expected to demonstrate the fastest CAGR of 57% from 2021 to 2028 as these are cellular technologies prove to be beneficial in transferring data in the connected drug delivery devices. Moreover, these devices overcome the limitations, such as the requirement of a hub and a companion device.

Regional Insights

North America led the global market in 2020 and accounted for a revenue share of over 34%. The region is expected to retain its leading position during the forecast years owing to the high per capita healthcare expenditure, quick adoption of the latest technologies and devices, and rising awareness regarding the adverse effects of non-compliance with drug therapy.

Europe is anticipated to be the fastest-growing regional market over the forecast period owing to the increasing cases of chronic diseases as well as the presence of a large target population base. In regions, such as Asia Pacific (excluding Australia and Japan), Latin America, and MEA, the product demand is expected to remain low in the coming years mainly due to the high costs of these devices. However, with the increasing number of market entrants, the product prices are expected to decrease over time; this will support the market development in such regions.

Key Companies & Market Share Insights

The market leaders are involved in acquisitions and strategic collaborations to withstand the competition. Companies are also investing in product launches to enhance their market position. For instance, in August 2020, Propeller Health entered the Japanese market by launching its digital health sensor for New Enerzair and Atectura Breezhaler asthma medications.

Owing to the global pandemic, there has been a significant demand for connected drug delivery devices as they can be used without the help of healthcare professionals. Patients and healthcare providers are adopting remote monitoring as well as self-management devices, which is likely to provide immense opportunities for market players to demonstrate the effectiveness of their products. Some of the prominent players in the connected drug delivery devices market are:

  • Propeller Health

  • Teva Pharmaceutical Industries Ltd.

  • BIOCORP

  • Merck KGaA

  • Adherium Ltd.

  • West Pharmaceutical Services, Inc.

  • Aterica

  • Phillips Medisize

  • FindAir

  • Elcam Medical

Connected Drug Delivery Devices Market Report Scope

Report Attribute

Details

The market size value in 2021

USD 279.34 million

Revenue forecast in 2028

USD 4,078.77 million

Growth rate

CAGR of 46.7% from 2021 to 2028

Base year for estimation

2020

Actual estimates/Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million/billion and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

Segments covered

Product, end-user, technology, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Brazil; Mexico; South Africa; Saudi Arabia

Key companies profiled

Propeller Health; Teva Pharmaceutical Industries Ltd.; BIOCORP; Merck KGaA; Adherium Ltd.; West Pharmaceutical Services, Inc.; Aterica; Phillips Medisize; FindAir; Elcam Medical

Customization scope

Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the globally connected drug delivery devices market report on the basis of product, end-user, technology and region:

  • Product Outlook (Revenue, USD Million, 2016 - 2028)

    • Connected Sensors

      • Connected Inhaler Sensors

      • Connectable Injection Sensors

    • Integrated Connected Devices

      • Connected Inhalation Devices

      • Connected Injection Devices

  • End-user Outlook (Revenue, USD Million, 2016 - 2028)

    • Healthcare Providers

    • Homecare

  • Technology Outlook (Revenue, USD Million, 2016 - 2028)

    • Bluetooth

    • NFC

    • Other Technologies

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.